EY3238 (EY-3238) is a novel and potent JAK2-HDAC dual inhibitor based on pacritinib with anticancer activity. It inhibits JAK2-HDAC dual targets with low nanomolar activity.

纯度：≥98%

CAS：1995861-12-5